VA-NEUSTAR-INC.
13.10.2021 09:02:08 CEST | Business Wire | Press release
Neustar Inc., a global information services and technology company and leader in identity resolution, today announces the redesign of the company’s Partner Program, renamed ‘Ultra Secure Partner Program’ (USPP). Providing enhanced channel access to its unmatched range of cloud-based security solutions, globally distributed network, and mature family of security services, partners can now easily curate and grow their cloud security portfolios.
In addition, Neustar Security Solutions also announces the appointment of Jeremy Nicholls as Vice President of Global Channels. The move comes as part of a wider effort to further grow the company’s channel business.
Ahead of joining Neustar in January 2021, Jeremy was Vice President of Global Channels & Alliances at Arbor Networks for 9 years. He has also held channel and direct sales leadership roles at Niksun, Polycom, and Ericsson and holds an MBA from Bath University in the UK.
Ultra Secure Partner Program
The newly designed program provides a clearly defined tiered structure for its partners to operate within, ensuring clarity on expectations from both parties, with consistent practices, policies, and discounts. Now a standardized, tiered program, the USPP offers varying benefits and expectations to partners depending upon the commitment made, with benefits increasing in higher tiers.
Higher levels of partnership have benefits including, but not limited to: higher discounting, qualified sales leads, training and support, account mapping, access to Neustar specialists and expertise, and focused marketing support, such as promotional materials, customizable collateral, special program funding, and case studies, to help partners generate more business. Discounts offered throughout the program have been increased to afford leading margins to partners, with rates varying by partner tier and reflective of partner engagement levels.
“We’ve reimagined Neustar Security Solutions’ partner program to make it as compelling as possible. Now a simple and value-driven program based on partner engagement levels, we offer highly competitive margins and unrivalled support to our partners ,” said Jeremy Nicholls. “As the world continues to move to the cloud, Neustar Security Solutions is uniquely positioned to partner with organisations who want to grow existing, and secure new customers based around cloud security, where they can wrap their own incremental services to the offerings. ”
Ed Lorenzini, CEO, Analyze Corporation said: “Neustar Security Solutions is a trusted partner of Analyze Corporation. This revamped and standardised program makes growing our business easier and even more rewarding. By participating in Neustar’s USPP, we are able to provide our customers with world-leading security solutions, support and insights that map to their cloud needs.”
Güngör Gündoğdu, Managing Director, Inforte added: “In this growing landscape, we at Inforte have found a valued partner in Neustar Security Solutions. By participating in Neustar’s USPP, our work together is smooth and straightforward, from customer registration through to delivery.”
The new channel partner programs are specifically targeted to expand sales and support coverage for Neustar Security Solutions in the United States, Canada, and Europe, with additional opportunities in Latin America and Eastern Europe.
For more information about the program, visit https://www.home.neustar/about-us/partners/security-partners or contact partners@team.neustar for a direct engagement.
About Neustar
Neustar is an information services and technology company and a leader in identity resolution providing the data and technology that enables trusted connections between companies and people at the moments that matter most. Neustar offers industry-leading solutions in Marketing, Risk, Communications, and Security that responsibly connect data on people, devices and locations, continuously corroborated through billions of transactions. Neustar serves more than 8,000 clients worldwide, including 60 of the Fortune 100. Learn how your company can benefit from the power of trusted connections here: https://www.home.neustar
# # #
View source version on businesswire.com: https://www.businesswire.com/news/home/20211013005047/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom